A Phase 1 trial combining ibrutinib and lenalidomide in relapsed chronic lymphocytic leukemia achieved durable disease control but reported unexpected serious cardiac toxicities. Investigators characterized the cardiac risk as a limiting factor for the regimen’s continued development. The update underscores the importance of cardiac monitoring when combining pathway inhibitors with immunomodulatory drugs, particularly in older or comorbidity-heavy CLL populations. Strategically, the results may prompt protocol modifications, patient-exclusion refinement, or re-scoped combination testing aimed at preserving efficacy while reducing cardiovascular signal.
Get the Daily Brief